Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer

A mucin degrader for cancer therapy

Nature Biotechnology volume 42, pages 572–573 (2024)Cite this article

Subjects

A new approach to targeting mucins via protein degradation shows promise against cancer.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Action of the HER2-targeted mucinase anti-HER2–eStcE and the resultant change in immunological landscape.

References

  1. Pedram, K. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01840-6 (2023).

    Article  PubMed  Google Scholar 

  2. Brockhausen, I. & Melamed, J. Glyconj J. 38, 459–474 (2021).

    Article  CAS  Google Scholar 

  3. Pearce, O. M. T. Glycobiology 28, 670–696 (2018).

    Article  CAS  PubMed  Google Scholar 

  4. Kufe, D. W. Oncogene 32, 1073–1081 (2013).

    Article  CAS  PubMed  Google Scholar 

  5. Beatson, R. et al. Nat. Immunol. 17, 1273–1281 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Piyush, T. et al. Cell Death Differ. 24, 1937–1947 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Paszek, M. J. et al. Nature 511, 319–325 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Taylor-Papadimitriou, J., Burchell, J. M., Graham, R. & Beatson, R. Biochem. Soc. Trans. 46, 659–668 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Békés, M., Langley, D. R. & Crews, C. M. Nat. Rev. Drug Discov. 21, 181–200 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Phillips, G. L. et al. Breast Cancer Res. Treat. 191, 303–317 (2022).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Inflammation and Tissue Repair, University College London, London, UK

    Richard Beatson

  2. School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK

    Richard Beatson & Joy M. Burchell

Authors
  1. Richard Beatson
    View author publications

    Search author on:PubMed Google Scholar

  2. Joy M. Burchell
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Joy M. Burchell.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beatson, R., Burchell, J.M. A mucin degrader for cancer therapy. Nat Biotechnol 42, 572–573 (2024). https://doi.org/10.1038/s41587-023-01984-5

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-023-01984-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer